Updates are available Correction dated 2024-10-18
Click to view Correction: https://doi.org/10.1007/s13555-024-01269-y
-
Authors
Silverberg, Jonathan I. https://orcid.org/0000-0003-3686-7805
Wollenberg, Andreas https://orcid.org/0000-0003-0177-8722
Stein Gold, Linda https://orcid.org/0000-0002-2758-1605
Del Rosso, James https://orcid.org/0000-0003-4215-7340
Yosipovitch, Gil https://orcid.org/0000-0001-6303-1822
Lio, Peter https://orcid.org/0000-0001-7600-0152
Carrascosa, Jose-Manuel https://orcid.org/0000-0003-4266-0771
Gallo, Gaia
Ding, Yuxin
Xu, Zhenhui https://orcid.org/0000-0003-0821-1008
Casillas, Marta https://orcid.org/0000-0002-6339-5279
Pierce, Evangeline https://orcid.org/0000-0002-8287-2835
Agell, Helena
Ständer, Sonja https://orcid.org/0000-0003-3612-7786
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04146363 at ClinicalTrials.govnct04178967 at ClinicalTrials.govDocuments that mention this clinical trial
Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01199-9
Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks
https://doi.org/10.1007/s13555-024-01225-w
Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
https://doi.org/10.1007/s13555-024-01226-9
Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)
https://doi.org/10.1007/s12325-024-02974-y
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01158-4
Documents that mention this clinical trial
Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks
https://doi.org/10.1007/s13555-024-01225-w
Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment
https://doi.org/10.1007/s13555-024-01226-9
Improvement Across Dimensions of Disease with Lebrikizumab Use in Atopic Dermatitis: Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Monotherapy Trials (ADvocate1 and ADvocate2)
https://doi.org/10.1007/s12325-024-02974-y
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis
https://doi.org/10.1007/s13555-024-01158-4
-
Funding
Funding for this research was provided by:
Dermira
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 1 April 2024
Accepted: 28 June 2024
First Online: 10 August 2024
Change Date: 18 October 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13555-024-01269-y
Declarations
:
: Jonathan I Silverberg has received grants and/or personal fees from AbbVie, AFYX Therapeutics, Arena Pharmaceuticals, Asana BioSciences, Bluefin, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly and Company, Galderma, GSK, Incyte, Kiniksa, LEO Pharma, Luna Pharma, Menlo Therapeutics, Novartis, Pfizer, RAPT Therapeutics, Regeneron, and Sanofi. Andreas Wollenberg has served as an advisor and/or paid speaker for and/or participated in clinical trials (with honorarium paid to the institution) sponsored by AbbVie, Aileens, Alentis, Almirall S.A., Amgen, Beiersdorf, Bioderma, Bioproject, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, DKSH, Eli Lilly, Galapagos, Galderma, Glenmark, GSK, Hans Karrer, Hexal, Janssen-Cilag, Kyowa Kirin, Leo Pharma, L’Oreal, Maruho, MedImmune, MSD, Mylan, MSD, Novartis, Pfizer, Pierre Fabre, Regeneron, Sandoz, Santen, Sanofi-Aventis, and UCB. Linda Stein Gold has served as an investigator/consultant and/or speaker for Amgen, AbbVie, LEO Pharma, Arcutis, Incyte, Dermavant, Sanofi, Regeneron, Eli Lilly and Company, Bristol Myers Squibb, UCB, Janssen, Ortho Derm, and Galderma. James Del Rosso has received grants as an investigator, honoraria for lecturing, and/or consulting fees from AbbVie, Amgen (Celgene), AOBiome, Aslan, Arbonne, Arcutis, Bausch Health (Ortho Derm), Bristol Myers Squibb, Dermavant, Dermira, Eli Lilly and Company, Exeltis, Ferndale, Galderma, Incyte, IntraDerm, Johnson & Johnson, La Roche-Posay/L’Oréal, LEO Pharma, Menlo Therapeutics, Nektar, Pfizer, Pierre Fabre,, Regeneron/Sanofi Genzyme, Sun Pharma, Theraplex, UCB Pharma, Unilever, and Verrica Pharmaceuticals. Gil Yosipovitch has conducted clinical trials or received honoraria for serving as a member of the Scientific Advisory Board of AbbVie, Eli Lilly, GSK, Novartis, Regeneron, Sanofi, Galderma, Pfizer, Kiniksa, Escient, Arcutis, and LEO Pharma and received research funds from Pfizer, Novartis, Eli Lilly, and Sanofi Regeneron. Peter Lio has received grants as an investigator, honoraria for lecturing, and/or consulting fees from AbbVie, AOBiome, Arbonne, Burt’s Bees, Dermavant, Dermira, Eli Lilly and Company, Exeltis, Franklin Bioscience/Altus Labs, Incyte, IntraDerm, Johnson & Johnson, Kiniksa, La Roche-Posay/L’Oréal, LEO Pharma, Menlo Therapeutics, The National Eczema Association, Pfizer, Pierre Fabre, Realm Therapeutics, Regeneron/Sanofi Genzyme, Theraplex, TopMD, UCB Pharma, Unilever, and Verrica Pharmaceuticals. Jose-Manuel Carrascosa has served as an advisor and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Almirall S.A., Amgen, Boehringer Ingelheim, Galderma, Janssen-Cilag, LEO Pharma, Eli Lilly, Novartis, Pfizer, Sanofi, Sandoz, and Bristol Myers Squibb. Gaia Gallo, Yuxin Ding, Marta Casillas, and Evangeline Pierce are employees and shareholders of Eli Lilly and Company. Zhenhui Xu is a full-time employee of CIMS Global LLC and a paid contractor for Eli Lilly and Company. Helena Agell is an employee of Almirall S.A. Sonja Ständer has served as an investigator for Celldex, Galderma, GSK, Incyte, Kiniksa Pharmaceuticals, and Trevi Therapeutics and has acted as a consultant, speaker, and/or served on advisory boards for AbbVie, Almirall S.A., Beiersdorf, Clexio Biosciences, Eli Lilly, Galderma, Incyte, IntegrityCE, Kiniksa Pharmaceuticals, Klirna, Pfizer, Professor Paul Gerson Unna Academy, Sanofi, TouchIME, Vifor Pharma, and WebMD.
: Both trials were approved by the applicable ethics review boards at each of the sites in North America, Europe, and the Asia–Pacific region. The main, central ethics review board was WCG IRB. A full listing of ethics review boards is in the <b>Supplementary Appendix</b>. Both trials were performed in accordance with the Helsinki Declaration of 1964 and its later amendments, the Council for International Organizations of Medical Sciences International Ethical Guidelines, and the International Conference on Harmonization Guidelines for Good Clinical Practice. All patients provided written informed consent to participate in the trials.
